Curis Lifesciences Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹7(5.47%)
Premium (ELP)
Curis Lifesciences Limited's successfully completed its Initial Public Offering and commenced trading on Nov 14, 2025 at the NSE exchange. The company raised 21,50,000 Shares through this public offering, comprising 21,50,000 Shares in fresh capital.
The IPO was priced within the band of ₹120 to ₹128, with minimum application lots of 1000 shares. The offering attracted significant investor interest during its subscription period from Nov 07, 2025 to Nov 11, 2025.
Share allotment was finalized on Nov 12, 2025, distributing equity to successful applicants. The stock's subsequent listing marked a significant milestone in the company's corporate history, providing public market liquidity to shareholders.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Curis Lifesciences Limited, founded in 2010, is a pharmaceutical company engaged in developing, manufacturing, and distributing a wide range of medicines. It produces pharmaceutical products for both domestic and global markets through loan license, contract manufacturing, and its own brand marketing. The company serves over 100 corporate clients under contract manufacturing and two clients for its own brands in Yemen and Kenya. Its product range includes tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments. The company operates a modern manufacturing facility in Sanand, Gujarat, maintaining strict quality standards, and as of July 31, 2025, it employs 95 permanent staff.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Experienced Leadership and Skilled Management: Promoters with 13–15 years of experience in the pharmaceutical sector and medical expertise lead the company, ensuring informed strategic decisions, operational efficiency, and sustained client trust.
- Broad and Diverse Product Range: Offers an extensive portfolio including tablets, capsules, oral liquids, external applications, and sterile ophthalmic ointments, supported by valid manufacturing licenses (G/25/2225 and G/28/1632).
- WHO-GMP Certified Facility with Global Reach: The Sanand, Gujarat-based manufacturing unit is WHO-GMP certified, strategically located for logistics and skilled workforce access, and holds international product registrations in markets such as Yemen, Kenya, the Philippines, and Nigeria.
- Operational Concentration Risk: Heavy reliance on a single manufacturing facility in Sanand, Ahmedabad (Gujarat) exposes the company to regional, environmental, and regulatory risks that could disrupt operations and impact financial performance.
- Regulatory and Approval Challenges: As part of a highly regulated sector, delays or lapses in obtaining or renewing statutory licenses, certifications, or product approvals may hinder business continuity and affect profitability.
- Debt Servicing and Compliance Risk: Previous delays in loan repayments pose potential reputational and financial risks; continued focus on disciplined financial management is crucial to maintain lender confidence and credit health.
- Mr. Dharmesh Dashrathbhai Patel
- Mr. Siddhant Jayantibhai Pawasia
- Mr. Piyush Gordhanbhai Antala
- Mr. Jaimik Mansukhbhai Patel
Curis Lifesciences Limited
Link Intime India Private Limited